ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.

News Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Equities

002940

CNE100003GC2

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
16.98 ^CNY	-0.88%		-5.09%	-21.79%

26/04	Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/04	Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	02/04	CI
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug	06/02	MT
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets	29/01	MT
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	02/01	CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	10/23/10	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.	30/23/30	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.	30/23/30	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates	17/23/17	MT
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China	27/23/27	MT
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China	16/23/16	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023	13/23/13	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022	25/23/25	CI
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm	06/23/06	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022	03/23/03	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Anglikang Pharma’s Drug to Lower Hypertension Fails to Make It on China’s Drug Procurement List	30/23/30	MT
Chinese Shares End Mixed; Anglikang Pharma Slides 8% on 191 Million Yuan M&A Plan	24/23/24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Equities

002940

CNE100003GC2

Summary

Filters